Lonza Group AG
LONN | SW
Overview
Corporate Details
- ISIN(s):
- CH0013841017 (+2 more)
- LEI:
- 549300EFW4H2TCZ71055
- Country:
- Switzerland
- Address:
- MÜNCHENSTEINERSTR. 38, 4052 BASEL
- Website:
- https://www.lonza.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Lonza Group is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
Market Cap data is planned for a future update.
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-27 07:00 |
Earnings Release
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
|
English | 12.7 KB | |
| 2025-05-27 02:00 |
Earnings Release
Lonza Publishes 2024 Comparative Financials Under One Lonza Organizational Stru…
|
English | 9.7 KB | |
| 2025-05-15 09:00 |
Board/Management Change
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
|
English | 14.6 KB | |
| 2025-05-15 02:00 |
Board/Management Change
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
|
English | 11.0 KB | |
| 2025-05-10 16:30 |
Declaration of Voting Results & Voting Rights Announcements
Lonza Announces Results of the 2025 Annual General Meeting All Motions Propose…
|
English | 16.3 KB | |
| 2025-05-09 06:30 |
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
|
English | 15.2 KB | |
| 2025-05-09 02:00 |
Earnings Release
Lonza Q1 2025 Qualitative Update: Strong Performance Across All Businesses in L…
|
English | 12.5 KB | |
| 2025-04-03 07:00 |
Report Publication Announcement
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual a…
|
English | 20.1 KB | |
| 2025-04-02 14:00 |
Regulatory News Service
Lonza Implements its Simplified and Streamlined Operating Model
|
English | 16.3 KB | |
| 2025-04-01 07:00 |
Transaction in Own Shares
Lonza Completes its Share Buyback Program
|
English | 12.2 KB | |
| 2025-01-30 06:25 |
Earnings Release
Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year an…
|
English | 40.1 KB | |
| 2025-01-29 06:25 |
Earnings Release
Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year an…
|
English | 40.1 KB | |
| 2025-01-29 01:00 |
Earnings Release
Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year an…
|
English | 34.9 KB | |
| 2025-01-29 01:00 |
Earnings Release
Lonza erzielt für 2024 ein solides Ergebnis mit konstantem Umsatz und 29.0% Ker…
|
German | 36.7 KB | |
| 2025-01-13 08:30 |
Regulatory News Service
Iconovo and Lonza to Collaborate on the Formulation Development of an Intranasa…
|
English | 9.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-12 | N/A | Executive member | Buy | None | 864,212.00 CHF |
| 2025-02-03 | N/A | Executive member | Sell | None | 79,257.80 CHF |
| 2025-01-31 | N/A | Executive member | Buy | None | 1,129,810.00 CHF |
| 2025-01-30 | N/A | Executive member | Buy | None | 35,392.00 CHF |
| 2024-07-26 | N/A | Executive member | Sell | None | 229,668.80 CHF |
| 2023-11-15 | N/A | Executive member | Buy | None | 7,088.00 CHF |
| 2023-11-01 | N/A | Executive member | Buy | None | 95,927.90 CHF |
| 2023-10-23 | N/A | Executive member | Buy | None | 327.30 CHF |
| 2023-10-19 | N/A | Executive member | Buy | None | 19,847.60 CHF |
| 2023-10-18 | N/A | Executive member | Buy | None | 19,481.00 CHF |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |